Amudha S.,
Sanjukta S. Rao,
Sweta Srivastava,
Raina M. P.,
Mary Margaret A.,
- Assistant Professor, Department of Molecular Biology and Genetics, St. Johns Medical College and Hospital, Bangalore, Karnataka, India
- Assistant Professor, Department of Medicine, St. Johns Medical College and Hospital, Bangalore, Karnataka, India
- HOD & Assistant Professor, Department of Transfusion Medicine & Immuno-Hematology, St. Johns Medical College and Hospital, Bangalore, Karnataka, India
- Technologist, Department of Molecular Biology and Genetics, St. Johns Medical College and Hospital, Bangalore, Karnataka, India
- Senior Technician, Department of Molecular Biology and Genetics, St John’s Hospital, Bangalore, Karnataka, India
Abstract
Introduction: Chronic Myelogenous Leukemia is a malignancy that affects the hematopoietic stems cells (HSC) of the bone marrow, leading to the rapid and continual proliferation of granulocytes and precursor blast cells. This is caused due to a reciprocal translocation that occurs between chromosomes 9 and 22, leading to the formation of derivative 22 also called as Philadelphia (Ph) chromosome. The Ph chromosome then encodes a fusion oncoprotein that functions as a tyrosine kinase activator encouraging cellular functions such as cell proliferation and rapid division and providing resistance to apoptosis. CML has been classified into different phases, based on the blast percentage, with symptoms becoming severe as the condition progresses to advanced phases. While the primary marker for this condition tends to be the Philadelphia chromosome, it has been observed that additional Ph observed in accelerated phase is a very important prognostic marker and we present a single case report with isodicentric Ph chromosome. Additional Ph presented as isodicentric is a rare cytogenetic phenomenon associated with CML and the clinical outcome is discussed.
Keywords: Philadelphia-Chromosomes, translocation, Chronic Myeloid Leukemia, Isodicentric, Prognostic Marker
[This article belongs to Research and Reviews: Journal of Oncology and Hematology ]
Amudha S., Sanjukta S. Rao, Sweta Srivastava, Raina M. P., Mary Margaret A.. Extra Philadelphia in CML Due to Isodicentric 22: A Case Report. Research and Reviews: Journal of Oncology and Hematology. 2025; 14(03):18-22.
Amudha S., Sanjukta S. Rao, Sweta Srivastava, Raina M. P., Mary Margaret A.. Extra Philadelphia in CML Due to Isodicentric 22: A Case Report. Research and Reviews: Journal of Oncology and Hematology. 2025; 14(03):18-22. Available from: https://journals.stmjournals.com/rrjooh/article=2025/view=232982
References
- Eden RE, Coviello JM. Chronic myelogenous leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 30285354.
- Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25(1):85–109. PMID: 14427847.
- Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: A model disease of the past, present and future. Cells. 2021;10(1):117. PMID: 33435150; PMCID: PMC7827482. doi: 10.3390/cells10010117.
- Sampaio MM, Santos MLC, Marques HS, Gonçalves VLS, Araújo GRL, Lopes LW, et al. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol. 2021;12(2):69–94. PMID: 33680875. doi: 10.5306/wjco.v12.i2.69.
- Senapati J, Sasaki K. Chromosomal instability in chronic myeloid leukemia: Mechanistic insights and effects. Cancers (Basel). 2022;14(10):2533. doi: 10.3390/cancers14102533.
- Sakthivel KM. Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia. Front Oncol. 2019;9:88. doi: 10.3389/fonc.2019.00088.
- Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5(4):1102–9. PMID: 33616651; PMCID: PMC7903225. doi: 10.1182/bloodadvances.2020003570.
- Seghatoleslami M, Ketabchi N, Ordo A, Asl JM, Golchin N, Saki N. Coexistence of p190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis: A case report. Mediterr J Hematol Infect Dis. 2016;8(1):e2016002. PMID: 26740863; PMCID: PMC4696471. doi: 10.4084/MJHID.2016.002.
- Sgherza N, Abruzzese E, Perla G, Minervini MM, Chiello V, Sciannamè N, et al. Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: Case report and revision of literature. Ther Clin Risk Manag. 2017;13:751–5. doi: 10.2147/TCRM.S137103.
- Greulich-Bode KM, Heinze B. On the power of additional and complex chromosomal aberrations in CML. Curr Genomics. 2012;13(6):471–6.
- Trombetti S, Cesaro E, Catapano R, Sessa R, Lo Bianco A, Izzo P, et al. Oxidative stress and ROS-mediated signalling in leukaemia: Novel promising perspectives to eradicate chemoresistant cells in myeloid leukaemia. Int J Mol Sci. 2021;22(5):2470. doi: 10.2174/138920212802510466.
- Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, et al. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica. 2010;95(9):1604–7. doi: 10.3324/haematol.2009.019109.
- Shaffer LG, McGowan-Jordan J, Schmid M, editors. An international system for human cytogenetic nomenclature. Basel: Karger; 2020. Published in collaboration with Cytogenet Genome Res.
- Barch MJ, Knutsen T, Spurbeck JL, editors. The AGT cytogeneticists laboratory manual. 4th ed. Philadelphia: Lippincott Raven; 2018.
- Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 1993;11(Suppl 1):11–5.
Research and Reviews: Journal of Oncology and Hematology
| Volume | 14 |
| Issue | 03 |
| Received | 25/04/2025 |
| Accepted | 15/09/2025 |
| Published | 25/11/2025 |
| Publication Time | 214 Days |
Login
PlumX Metrics